Article

A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease

2024-09-22

Abstract excerpt

<h4>ABSTRACT</h4> The inflammatory bowel diseases (IBD) known as Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract believed to arise because of an imbalance between the epithelial, immune and microbial systems. It has been shown that biological differences (genetic, epigenetic, microbial, environmental, etc.) exist between patients with IBD, with mult...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5758eb17-ae9f-56cb-a088-9b52e055c5bd
DOI: 10.1101/2024.09.19.24314034

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel DiseaseDOI 10.1101/2024.09.19.24314034Read

Multi-omics phenotyping characterizes molecular divergence underlying different clinical scenarios of inflammatory bowel diseaseSemantic proximity Read

A distinct serum metabolic signature outperforms C-reactive protein as a non-invasive marker for monitoring disease activity in Inflammatory Bowel DiseaseSemantic proximity Read

Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profilingSemantic proximity Read

Identifying Robust Biomarkers for the Diagnosis and Subtype Distinction of Inflammatory Bowel Disease through Comprehensive Serum Metabolomic ProfilingSemantic proximity Read

New Metabolic and Genetic Biomarkers for Diagnosis of Ulcerative ColitisSemantic proximity Read

Proteomics and metabolomics in inflammatory bowel disease.Semantic proximity Read

Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitisSemantic proximity Read

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel diseaseSemantic proximity Read

Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases.Semantic proximity Read

Multi-omics empowered deep phenotyping of ulcerative colitisSemantic proximity Read

Targeted 1H NMR metabolomics and immunological phenotyping of human fresh blood and serum samples discriminate between healthy individuals and inflammatory bowel disease patients treated with anti-TNF.Semantic proximity Read

Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.Semantic proximity Read